Trials / Not Yet Recruiting
Not Yet RecruitingNCT05971589
A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors
An Exploratory Clinical Study Evaluating the Safety, Tolerance, Immune Response, and Initial Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) LM103 Injection in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients. The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LM103 | Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion. |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2026-04-01
- Completion
- 2026-08-01
- First posted
- 2023-08-02
- Last updated
- 2023-08-02
Source: ClinicalTrials.gov record NCT05971589. Inclusion in this directory is not an endorsement.